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INTRODUCTION
Schizophrenia is a disorder with impaired functioning for a 
significant portion of the time since the onset of the distur-
bance.1 Impairment in one or more major areas of function-
ing, such as work or interpersonal relations can be found not 
only in chronic, multi-episodes schizophrenia patients but also 
in first-episode patients and even in individuals at ultra-high 
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risk (UHR) for psychosis.2,3 In UHR individuals, baseline low 
functional level or declining of functional level during few 
years of follow-up was reported to be significant predictor of 
transition into overt psychotic disorder.4 The psychosocial dys-
function in first-episode patients5,6 was generally reported to 
be associated with negative symptoms rather than positive 
symptoms. These findings indicate that functional decline may 
be not chronic illness-related factor or effect of drugs such as 
antipsychotics rather trait of the disease itself, which can be 
derived from the lesions of the neurodevelopmental origin.7
There were some different pictures of psychosocial dysfunc-
tion depending on the phase of illness and domains of func-
tioning. The social function in UHR was shown to be significant-
ly compromised, and the extent of impairment was comparable 
to that of first-episode and multi-episode schizophrenia pa-
tients. Meanwhile, role function in UHR was significantly 
ORIGINAL ARTICLE
Impaired Social and Role Function in Ultra-High Risk  
for Psychosis and First-Episode Schizophrenia:  
Its Relations with Negative Symptoms
So Jung Lee1, Kyung Ran Kim1,2, Su Young Lee2,3, and Suk Kyoon An1,2,4 
1Department of Psychiatry, Yonsei University College of Medicine, Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea
2Section of Self, Affect and Neuroscience, Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea 
3 Department of Psychiatry, Cheil General Hospital & Women’s Healthcare Center, Dankook University College of Medicine, Seoul,  
Republic of Korea
4Graduate Program in Cognitive Science, Yonsei University, Seoul, Republic of Korea
ObjectiveaaPsychosocial dysfunction was a nettlesome of schizophrenia even in their prodromal phase as well as first episode and its 
relations with psychopathology were not determined. The aim of the present study was to examine whether the social and role function 
impairment was found in ultra-high risk for psychosis (UHR) individuals as well as first-episode schizophrenia patients and to explore 
its relations with psychopathology.  
MethodsaaThirty-seven normal controls, 63 UHR participants and 28 young, first-episode schizophrenia patients were recruited. Psy-
chosocial functioning was examined by using Global function: Social and Role scale. Psychopathologies of positive, negative and depres-
sive symptom were also measured. 
ResultsaaSocial and role functioning in UHR were compromised at the equivalent level of those of first-episode schizophrenia patients. 
Multiple linear regression analysis revealed that social and role dysfunction was associated with negative symptoms in each UHR and 
first-episode schizophrenia group. 
ConclusionaaThese findings suggest that the significant impairment of social and role function may be appeared before the active psy-
chosis onset at the level of extent to those of first-episode schizophrenia patients. The psychosocial intervention strategy especially tar-
geting the negative symptoms should be developed and provided to individuals from their prepsychotic stage of schizophrenia. 
 Psychiatry Investig 2017;14(2):186-192
Key Wordsaa Schizophrenia, First episode, Ultra-high risk, Social dysfunction, Role dysfunction.
Received: May 31, 2016    Revised: August 1, 2016
Accepted: August 3, 2016    Available online: October 13, 2016
 Correspondence: Suk Kyoon An, MD, PhD
Department of Psychiatry, Yonsei University College of Medicine, Severance 
Hospital, Yonsei University Health System, 50-1 Yonsei-ro, Seodaemun-gu, 
Seoul 03722, Republic of Korea
Tel: +82-2-2228-1585, Fax: +82-2-313-0891, E-mail: ansk@yuhs.ac
cc  This is an Open Access article distributed under the terms of the Creative Commons 
Attribution Non-Commercial License (http://creativecommons.org/licenses/by-
nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduc-
tion in any medium, provided the original work is properly cited.
https://doi.org/10.4306/pi.2017.14.2.186
SJ Lee et al.
   www.psychiatryinvestigation.org  187
declined to that of first-episode patients but better than that 
of multi-episode patients.8 Furthermore, it was reported that 
role functioning did not predict later psychosis transition inde-
pendently of social functioning in UHR.9 
In schizophrenia, there were heterogeneous findings on the 
relationship of psychosocial disability with psychopathologies 
including negative symptoms10-19 and depressive symptoms.13,16,20 
These mixed findings may be resulted from the clinical status of 
schizophrenia (first episode15,19 vs. multi-episode or mixed),10-14,16-18,20 
psychosocial function measurement tools [objective mea-
sures10,11,13-15,17-20 vs. subjective measures11-13,16] and other fac-
tors. In UHR, most studies found that the psychosocial im-
pairment was associated with negative symptoms21-25 while few 
reports showed the relations with depressive symptoms.25-27 
Overall, the previous studies suggest that the negative symp-
toms rather than depressive and positive one showed strong 
association with objectively-assessed psychosocial disability 
in UHR and early-stage schizophrenia patients. Therefore, 
greater knowledge concerning the social and role functioning 
and its relations with prodromal psychopathologies would 
provide the clues for the development of the indicated pre-
vention and early intervention strategies in these help-seeking 
clinical groups. 
The aim of the study was to examine whether the social and 
role function impairment was found in UHR individuals as 
well as first-episode schizophrenia patients and to explore its 
relations with psychopathology. Based on the previous studies, 
our hypothesis was that both clinical groups showed social 
and role functioning deficits and the extent of these deficits in 
both groups may be comparable. In addition, we also expected 
that social and role disability may be associated with negative 
symptoms rather than positive and depressive symptoms. 
For explorative purpose, we observed the relations of social 
and role dysfunction with two major negative items of affec-
tive flattening and avolition, which have not yet been studied 
extensively in these clinical groups. 
METHODS
Participants
The participants were consisted of normal controls (NC), 
individuals at UHR for psychosis, and first-episode schizo-
phrenia patients. 37 NC were recruited from internet adver-
tisements. The 63 UHR participants were from the “Clinic 
FORYOU” at Severance Hospital of Yonsei University Health 
System between July 2007 and June 2009. The Clinic FORY-
OU was established in March 2007 as an UHR research clinic 
of the “GRAPE” (Green Program for Recognition and Pre-
vention of Early Psychosis) project. The 28 young first-epi-
sode patients with schizophrenia enrolled in our study were re-
cruited from both the outpatient (15) and inpatient (13) service 
units of Severance Hospital and Severance Mental Health 
Hospital of Yonsei University Health System during the same 
time period. All patients with schizophrenia were in clinically 
stable or stabilization phase. All participants met the inclusion 
criteria of being between 15–35 years old and having more 
than nine years of education. Participants were evaluated by 
using the Structured Clinical Interview for the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-IV).28,29 
The exclusion criteria were current or past history of neuro-
logical illness or traumatic brain injury; current or past psy-
chiatric illness history for the NC; and current or past diagno-
sis of major psychiatric disorder with psychotic features for 
UHR patients.
The UHR participants were diagnosed by the Criteria of 
the Prodromal Syndromes of SIPS.30 The DSM-IV diagnoses 
of the UHR participants were as follows: any mood disorder, 
including any depressive (n=23)/bipolar disorder (n=1); any 
anxiety disorder (n=14), including social phobia (n=9); any 
eating disorder (n=1); other axis I disorder (n=2) and schizo-
typal personality disorder (n=5). The diagnosis of schizophre-
nia was made according to the criteria of the DSM-IV using 
the SCID.29 This study was carried out in accordance with the 
Declaration of Helsinki. The Institutional Review Boards at 
Severance Hospital and Severance Mental Health Hospital re-
viewed and approved this study. All participants were given 
written informed consent. Written informed consent was ob-
tained from all subjects and additionally from the parents if 
subjects were under 18 years of age.
Measures
Global functioning: Social (GF: Social) and Global 
functioning: Role (GF: Role)
In this article, we used the Global functioning: Social (GF: 
Social)31 and Global functioning: Role (GF: Role)32 to assess the 
psychosocial functioning in the participants. Score of the both 
scales range from 1 to 10, with 10 indicating superior func-
tioning and 1 indicating extreme dysfunction. To increase reli-
ability, both scales include focused and detailed anchor points 
for each rating interval. Experienced clinicians summarized 
other previously collected data and directed interview guided 
by the accompanying probes. Each scale generates 3 scores: 
current functioning which is the lowest level of functioning in 
the past month, lowest and highest level of functioning report-
ed over the past year. In the present study, we used the present 
level of functioning. 
The GF: Social scale rated quantity and quality of age ap-
propriate intimate relationships, peer relationships, level of 
peer conflict, and involvement with family members. Interac-
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tions with people other than family members got higher score 
than interactions limited only to family members. Etiology of 
social dysfunction or levels of clinical symptomatology were 
not considered when rating the scale. The GF: Role scale em-
phasized the level of support provided within the individual’s 
environment and the individual’s performance given such 
support in addition to age appropriateness. The ratings were 
based on performance in school, work, or home.
Other psychosocial measures
To assess psychopathologies and symptom severities, the 
scale for the assessment of positive symptoms (SAPS),33 the 
scale for the assessment of negative symptoms (SANS),34 the 
Montgomery-Asberg Depression Rating Scale (MADRS)35 
were used. The sum of summary scores of 4 items of SAPS and 
5 items of SANS were used. In addition, the summary scores 
of affective flattening or blunting and avolition-apathy were 
used for further exploration, since these 2 items were proposed 
to be particularly prominent in schizophrenia.1
Procedure
Clinical interviews and assessments were administered by 
a psychiatrist within a week after recruitment into the study. 
Statistical analysis
To compare the GF: Social and GF: Role between the three 
groups, multivariate analyses of variance (ANOVA) were 
used. Post-hoc analysis was done also with Bonferroni correc-
tion. Pearson correlations of two GF scales with psychopa-
thologies were conducted by using the SANS, SAPS, MADRS 
in each clinical group. All variables significantly correlated 
with GF: Social and GF: Role scores were analyzed subse-
quently using a multiple linear regression to evaluate their in-
dependent and primary contributions to each GF: Social and 
GF: Role scores. Stepwise method was utilized in the regres-
sion model, and pairwise deletion was utilized for missing 
data. For exploration of association with specific negative 
symptom items such as affective flattening or blunting and avo-
lition-apathy, the same statistical analysis was also conducted. 
A significance level of p less than 0.05 was used for all tests. 
RESULTS
Demographic and clinical profiles of the participants
There was no difference between the three groups in age, to-
tal durations of education, or distribution of sex (Table 1). The 
UHR patients and first-episode schizophrenia patients both 
showed more positive, negative and depressive symptoms than 
normal controls. First-episode schizophrenia patients showed 
more positive and less depressive symptoms than UHR pa-
tients. The difference of negative symptoms between UHR pa-
tients and first-episode schizophrenia did not reach a signifi-
cant level.
Table 1. Demographic and clinical profiles of normal controls, ultra-high risk (UHR) for psychosis, and first-episode schizophrenia patients
Normal controls 
(N=37)
UHR for psychosis 
(N=63)
First-episode schizophrenics 
(N=28)
Age (years) 20.6 (3.1) 19.7 (3.5) 20.6 (2.7)
Education (years) 13.2 (1.7) 12.6 (1.8) 12.8 (1.9)
Sex (M/F) 17/20 38/25 13/15
SIPS-defined prodromal status (BIPS/APS/GRDS) 10/57/8
Type (paranoid/undifferentiated/residual) 23/3/2
Positive symptoms of SAPS*†‡ 0.0 (0.0) 3.2 (2.2) 6.4 (2.8)
Negative symptoms of SANS*† 0.5 (0.2) 7.9 (4.3) 8.8 (4.8)
Depressive symptoms of MADRS*†‡ 1.3 (3.2) 21.2 (10.1) 15.7 (10.4)
Antipsychotic medications 
Naïve/medicated‡ 38/25 1/27
Chlorpromazine equivalent dose (mg/d)‡ 135.3 (103.3) 445.7 (324.6)
*significant difference between normal controls and UHR patients for psychosis (p<0.05), †significant difference between normal controls 
and first-episode schizophrenia patients (p<0.05), ‡significant difference between UHR for psychosis and first-episode schizophrenia patients 
(p<0.05). SAPS (Andreason, 1983): Scale for Assessment of Positive Symptoms, 2 UHR data are missing, SANS (Andreason, 1983): Scale for 
Assessment of Negative Symptoms, 2 UHR data are missing, SIPS (McGlashan et al., 2003): Structured Interview for Prodromal Syndromes; 
MADRS (Montgomery and Asberg, 1979): Montgomery-Åsberg Depression Rating Scale, 4 First-episode schizophrenics data are missing. 
BIPS: Brief Intermittent Psychotic Symptom Prodromal Syndrome, APS: Attenuated Positive Symptom Prodromal Syndrome, GRDS: Genet-
ic Risk and Deterioration Prodromal Syndrome 
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Comparisons of Global functioning: Social 
(GF: Social) and Global functioning: Role (GF: Role) 
between UHR, first-episode schizophrenia and 
normal control groups
The GF: Social and GF: Role in normal controls, ultra-high 
risk (UHR) patients for psychosis, and first-episode schizo-
phrenia patients are shown in Table 2. Multivariate ANOVA 
revealed a significant difference between the groups overall 
[F(4,250)=29.4, p<0.001]. A follow-up series of univariate 
ANOVA showed significant differences for the GF: Social [F 
(2,125)=104.7, p<0.001] and GF: Role [F(2,125)=49.0, p< 
0.001]. As shown in Table 2, post hoc testing using the Bon-
ferroni correction showed that UHR participants and first-
episode patients exhibited a significantly impaired GF: Social 
than NC did (vs. UHR p<0.001, vs. FE p<0.001). Also, UHR 
participants and first-episode patients showed significantly 
impaired GF: Role than NC did (vs. UHR p<0.001, vs. FE 
p<0.001). UHR participants did not differ significantly from 
the first-episode patients (p>0.999) for GF: Social or GF: Role.
Preliminary correlations of Global functioning: 
Social (GF: Social) and Global functioning: Role 
(GF: Role) with psychopathology in individuals 
at ultra-high risk (UHR) for psychosis, and 
first-episode schizophrenia patients
Pearson’s correlation analysis revealed that in UHR pa-
tients (Table 3), GF: Social and GF: Role were significantly 
correlated with negative symptoms of SANS (r=-0.60, p<0.001; 
r=-0.42, p=0.001, in respect) and depressive symptoms of 
MADRS (r=-0.55, p=0.003; r=-0.40, p=0.001, respectively). 
In addition, GF: Social was significantly correlated with af-
fective flattening or blunting item and avolition-apathy item of 
SANS (r=-0.37, p<0.001; r=-0.51, p<0.001, in respect) and GF: 
Role was significantly correlated with avolition-apathy item 
of SANS (r=-0.40, p=0.002). 
In first-episode schizophrenia patients (Table 3), the Pear-
son’s correlation analyses showed that GF: Social were corre-
lated with negative symptoms of SANS (r=-0.49, p=0.008) 
and depressive symptoms of MADRS (r=-0.46, p=0.024) and 
GF: Role was correlated with negative symptoms of SANS 
r=-0.46, p=0.014). In addition, GF: Social was significantly 
correlated with avolition-apathy item of SANS (r=-0.47, 
p=0.011) and GF: Role was significantly correlated with avo-
lition-apathy item of SANS (r=-0.44, p=0.020). There were 
Table 2. Global functioning: Social (GF: Social) and Global functioning: Role (GF: Role) in normal controls, ultra-high risk (UHR) individuals 
for psychosis, and first-episode schizophrenia patients
Normal controls 
(N=37)
UHR patients for 
psychosis (N=63)
First-episode  
schizophrenia  
patients (N=28)
F-values, d.f.
p-values
Post-hoc
Corrected 
p-values
GF: social 8.6 (0.7) 4.8 (1.6) 4.9 (1.4) F(2,125)=104.7 N vs. U <0.001
p<0.001 N vs. S <0.001
U vs. S >0.999
GF: role 8.1 (0.9) 5.2 (1.7) 5.0 (1.7) F(2,125)=49.0 N vs. U <0.001
p<0.001 N vs. S <0.001
U vs. S >0.999
Corrected p=uncorrected p×3
Table 3. Correlations of Global functioning: Social (GF: Social) and Global functioning: Role (GF: Role) with psychopathology in ultra-high 
risk (UHR) individuals for psychosis, and first-episode schizophrenia patients
UHR patients for psychosis (N=63) First-episode schizophrenia patients (N=28)
GF: social GF: role GF: social GF: role
r p r p r p r p
Negative symptoms of SANS -0.60 <0.001 -0.42 0.001 -0.49 0.008 -0.46 0.014
Affective flattening or blunting of SANS -0.37 <0.001 -0.21 0.113 -0.35 0.069 -0.23 0.250
Avolition-apathy of SANS   -0.51 <0.001 -0.40 0.002 -0.47 0.011 -0.44 0.020
Positive symptoms of SAPS -0.19 0.136 -0.08 0.530 0.06 0.750 0.09 0.656
Depressive symptoms of MADRS -0.55 < 0.001 -0.40 0.001 -0.46 0.024 -0.05 0.809
SAPS (Andreason, 1983): Scale for Assessment of Positive Symptoms; 2 UHR data are missing; SANS (Andreason, 1983): Scale for Assess-
ment of Negative Symptoms; 2 UHR data are missing; MADRS (Montgomery and Asberg, 1979): Montgomery-Åsberg Depression Rating 
Scale; 4 First-episode schizophrenics data are missing
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no other significant correlations.
Multiple linear regression analysis of Global 
functioning: Social (GF: Social) and Global 
functioning: Role (GF: Role) with other variables
In UHR, overall full regression model was significant and 
the negative symptoms accounted for 35% of the variance in 
social dysfunction (β=-0.60, t=-5.76, p<0.001) and for 17% of 
the variance in role dysfunction (β=-0.42, t=-3.60, p=0.001). The 
positive symptoms (for social dysfunction: β=-0.08, t=-0.77, 
p=0.445; for role dysfunction: β=-0.01, t=-0.10, p=0.992) and 
depressive symptoms (for social dysfunction: β=-0.26, t=-1.87, 
p=0.066; for role dysfunction: β=-0.20, t=-1.22, p=0.227) were 
excluded. For specific negative items, overall full regression 
model was significant and the avolition-apathy item accounted 
for 26% of the variance in social dysfunction (β=-0.51, t=-4.55, 
p<0.001) and for 16% of the variance in role dysfunction (β=-0.51, 
t=-4.55, p<0.001). The affective flattening or blunting item (for 
social dysfunction: β=-0.13, t=-0.96, p=0.343; for role dysfunc-
tion: β=0.18, t=0.13, p=0.900) was excluded.
In first-episode schizophrenia patients, the negative symp-
toms accounted for 21% of the variance in social dysfunction 
(β=-0.49, t=-2.66, p=0.014) and for 17% of the variance in 
role dysfunction (β=-0.46, t=-2.41, p=0.025). The positive 
symptoms (for social dysfunction: β=0.04, t=0.21, p=0.839; 
for role dysfunction: β=0.07, t=-0.34, p=0.737) and depressive 
symptoms (for social dysfunction: β=-0.31, t=-1.59, p=0.127; 
for role dysfunction: β=0.16, t=0.75, p=0.460) were excluded. 
For specific negative items, overall full regression model was 
significant and the avolition-apathy item accounted for 19% of 
the variance in social dysfunction (β=-0.47, t=-2.74, p=0.011) and 
for 19% of the variance in role dysfunction (β=-0.44, t=-2.48, 
p=0.020). The affective flattening or blunting item (for social 
dysfunction: β=-0.05, t=-0.20, p=0.840; for role dysfunction: 
β=0.14, t=0.56, p=0.580) was excluded. The tolerance among 
the predictors did not indicate multi-collinearity (all VIF<1.1). 
A summary of regression analysis was shown in Table 4 and 5. 
DISCUSSION
The aim of the present study was first, to examine whether 
UHR individuals as well as first-episode schizophrenia pa-
tients would show significantly impaired social and role func-
tion, and second was to explore the relations between each 
function and psychopathologies such as positive, negative, and 
depressive symptoms. Our main findings were that UHR par-
ticipants and first-episode patients exhibited a significantly 
impaired social and role functioning than normal controls did. 
Meanwhile, decline of the social and role functioning in UHR 
were not different from those of first-episode schizophrenia 
patients, which matched with our hypothesis. Social and role 
function impairment were primarily and independently asso-
ciated with negative symptoms but not associated with de-
pressive nor positive symptom in each UHR and first-episode 
schizophrenia group. 
UHR participants as well as first-episode schizophrenia 
patients showed marked impairment in social and role func-
tion than normal control group. More importantly, the extent 
Table 4. Multiple linear regression analysis of Global functioning: Social (GF: Social) and Global functioning: Role (GF: Role) with psycho-
pathologies in each clinical group
Determinants
Participants
β* t P ΔR2† R2‡ F df p
UHR (N=63) GF: social Negative symptom -0.60 -5.76 <0.001 0.36 0.35 33.2 1,59 <0.001
GF: role Negative symptom -0.42 -3.60 0.001 0.18 0.17 13.0 1,59 0.001
First-episode schizophrenia  
  patients (N=28)
GF: social Negative symptom -0.49 -2.66 0.014 0.24 0.21 7.1 1,22 0.014
GF: role Negative symptom -0.46 -2.41 0.025 0.21 0.17 5.8 1,22 0.025
All VIF<1.1. *standardized coefficient, †changed variance, ΔR2, ‡adjusted R2, explained variance by model. UHR: ultra-high risk 
Table 5. Multiple linear regression analysis of Global functioning: Social (GF: Social) and Global functioning: Role (GF: Role) with specific 
negative item in each clinical group
Determinants
Participants
β* t P ΔR2† R2‡ F df p
UHR (N=63) GF: social Avolition-apathy item -0.60 -5.76 <0.001 0.26 0.25 20.7 1,59 <0.001
GF: role Avolition-apathy item -0.42 -3.66 0.001 0.16 0.14 10.9 1,59 0.002
First-episode schizophrenia  
  patients (N=28)
GF: social Avolition-apathy item -0.49 -2.66 0.014 0.22 0.19 7.5 1,26 0.011
GF: role Avolition-apathy item -0.46 -2.41 0.025 0.19 0.16 6.2 1,26 0.020
All VIF<1.1. *standardized coefficient, †changed variance, ΔR2, ‡adjusted R2, explained variance by model. UHR: ultra-high risk 
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of impairment in UHR group was comparable to that of first-
episode schizophrenia patients. These findings were compati-
ble to those of previous studies.2,3,8,17 It was suggested that the 
impairment in social and role functioning are already emerged 
from the putative prodromal phase at the equivalent level of 
first-episode schizophrenia patients, which is compatible to 
the neurodevelopmental model of schizophrenia.36
Psychosocial functional deficits for social and role domains 
were primarily associated with negative symptoms of SANS 
but not associated with depressive nor positive symptoms in 
each clinical group. At first, depressive symptoms and psy-
chosocial functioning seemed to have association with simple 
correlation, but it turned out to be not primarily related when 
we did the regression analysis. These findings were generally 
compatible to those of previous studies in first-episode schizo-
phrenia15,19 and UHR individuals.21-24 There were a few re-
ports of correlations of psychosocial dysfunction with depres-
sive symptoms in first-episode schizophrniea patients13,16,20 
and UHR individuals.25-27 However, this correlations with de-
pressive symptoms were only found when the assessment of 
psychosocial dysfunction was done by using subjective self-
rate measurement,13,16,20,25,26 except one.27 Generally, the self 
reported complaints of depression was not reported to be 
highly correlated with objective measure of depression at least 
partly due to the confounding effects of the personality char-
acteristics of subjects,36 which can be also a major associated 
factors of psychosocial functioning. Thus, the different find-
ings may be possible according to the measurements tools of 
the self-reported and objectively rated severity of depression, 
though the exact reason of these findings is uncertain. It is also 
noteworthy that the depressive symptoms should not be ne-
glected, since this psychopathology may be an another enhanc-
ing risk for transition of overt psychosis.37 The finding that the 
positive symptoms do not appear to be a major independent 
factor of psychosocial functional disability is compatible to 
the lack of effectiveness of current pharmacotherapy for the 
psychosocial disability in schizophrenia group. The extents of 
relationship between negative symptoms and social and role 
dysfunction in each clinical group were within the level of the 
moderate size (18–35%). Thus, to improve the social and role 
dysfunction, the psychosocial intervention strategy should 
address the negative symptoms. 
The limitations of our study should be noticed. First, the 
first-episode groups were in clinically stabilized state. Thus, 
our findings of association of functioning with the negative 
symptom not with the positive one cannot be generalized into 
the whole schizophrenia patients populations regardless of 
their psychotic symptoms status. Second, there was no follow-
up data to elucidate the causal relations of psychosocial func-
tional impairment and psychopathologies. Long-term follow-
up studies are needed to be our understanding of the important 
contributions of psychopathology to social and role dysfunc-
tion in UHR and first-episode schizophrenia patients. Lastly, 
the other variables such as neurocognitive and social cogni-
tive function are not assessed. These factors may be differen-
tially interacted with negative symptoms for developing im-
pairment of social and role functioning in these clinical groups. 
For long-term follow-up studies, all these factors should be pro-
mote our understanding of the whole pictures of psychosocial 
dysfunction in schizophrenia from their early prepsychotic stage. 
In conclusions, our study found that UHR participants 
showed significantly impaired social and role functioning at 
the level of the first-episode schizophrenia patients. In addi-
tion, in each stabilized clinical group, social and role dysfunc-
tion were primarily and independently associated with nega-
tive symptoms but not with depressive and positive symptoms. 
These findings implicate that the significant impairment of so-
cial and role function may be appeared before the active psy-
chosis onset in schizophrenia and thus the psychosocial inter-
vention especially targeting the negative symptoms should be 
actively provided in their prepsychotic stage and in their stabi-
lized states of schizophrenia. In near future, it is needed to be 
examined whether the improving the negative symptoms or 
psychosocial functioning would be play an important role for 
preventing the transition of UHR states into overt psychotic 
disorder. 
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